Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Doc: What happens if the market cap is 950 million on about June 1st?
I’m sorry that my comments offended your sense of reality.
ignatiusrielly35. Thank you for your reply. I am always learning how things work in this wonderful age of AI digital control. It's good for people to see the market they are investing in.
Broken Arrow.
Thanks ignatiusrielly35 for your market savvy.
Yep, soon, very soon and around the corner. Good! you picked up some buzzwords from clown Misleading...
Manipulators need to be taught a lesson... Talk to your senators and representatives, lets get this rolling, Where is bas2020? team up with him, he knows how to get this done, he has experience from another Miracle drug NWBO...FUDsters are suppressing the world's one and only miracle drug, which can cure anything on planet earth... Messiah Misleading deserves a Nobel Prize for bringing this drug to humanity....
It’s not possible. There is no feasible way for any private entity to trace transactions and accurately characterize them. The DTCC and the Prime Brokers like it to be opaque, despite proclaiming otherwise. Companies have tried to flush out naked shorts by, for example, issuing share dividends but the brokers just fabricate “accounting entry” shares. The only way it would ever be stopped is if they someday convert share identification to a blockchain, like crypto. Which will never happen because the large crooks basically control the market and the regulators and they make a lot of money from naked shorting.
ignatiusrielly35 - What about AVXL hiring a stock transaction auditor? Let's see who are transacting in stock activity and where the shares going? This should show who's naked shorting the stock. We can take the results to congress if the SEC doesn't act on it.
The flipside is that whatever the price is at the settlement date, the short scammers will absorb all of the forced selling they caused. Then their motivation to continue with their algo suppression will significantly abate leading into the EMA and/or FDA application. That is when we will likely see a nice rally.
There will be a tendency for other institutions to go long to try to capitalize on that. The market will get antsy, and may already be so. Hence the recent lack of non-stop downward action.
How exactly are 5 million shares “pre-covered” before they are sold/purchased? Surely you are not suggesting collusion? lol. For there are nowhere near that many options that would legally enable such covering. You are not suggesting that the short hedgies have already arranged the purchase, I hope. Again, lol.
Nope, nothing to see here. As I stated a while ago, the hedges/mm’s are intentionally forcing the Russell funds to sell shares. Welcome to the “efficient market” playground. (This is not intended for you, you know this already)
Drugs Advisory Committee (PCNS) on Monday, June 10, 2024, to discuss donanemab, which Eli Lilly and Company (NYSE: LLY) has submitted for the treatment of early symptomatic Alzheimer’s disease. The open public hearing portion of the meeting will be conducted virtually.
The Phase 3 study submitted as part of this application, TRAILBLAZER-ALZ 2, is a double-blind, placebo-controlled study to evaluate the safety and efficacy of donanemab in participants ages 60-85 years with early symptomatic Alzheimer's disease (mild cognitive impairment or mild dementia due to Alzheimer's disease) with the presence of confirmed Alzheimer's disease neuropathology. Alzheimer's disease is a progressive and fatal disease that in its early symptomatic stages affects 6-7.5 million Americans. The trial enrolled 1,736 participants, across eight countries, selected based on cognitive assessments in conjunction with amyloid plaque imaging and tau staging by positron emission tomography (PET) imaging.
The TRAILBLAZER-ALZ 2 study results were published in the Journal of the American Medical Association (JAMA). Lilly continues to study donanemab in multiple clinical trials, including TRAILBLAZER-ALZ-3, studying donanemab for the prevention of Alzheimer’s disease.
https://investor.lilly.com/news-releases/news-release-details/lilly-statement-fda-advisory-committee-meeting-donanemab-early
Expect a SHORT SQUEEZE for AVXL soon!!!
Good luck and GOD bless,
Many of the 22 M short shares are already covered. AVXL was about 3.75 on April 30 - rank day for the Russell reconstitution (compared to about 8.00 last year). We know for a fact that AVXL's proportion of the Russell 2000 and derivations thereof will be about 55% less on July 1 than the representation in the current index. About 8-10 million shares are held in Russell related funds --- hence +/- 5 million of the 22 million short coverage has been 'pre-purchased' with actual coverage occurring end of June. This is a done deal. If the market cap is under 300 million on May 31 (and MC is about that now), then the XBI will shed all 5 million shares on June 28. So 1/4 of the short position is already covered and another 1/4 could be covered in a couple weeks unless price goes up. The actual cancellation of the short position with the purchase of shed shares from the indices will occur on June 28.
Another thing for certain is that several posters will be absolutely amazed by the volume of shares traded AH on June 28.
George. Tell us something we don’t know. This is a daily occurrence. These algorithms and short bastards will never give up until the company is destroyed. The only hope is an approval somewhere which appears to be fleeting with der missing. Just what we need. Another presentation. Another downwave of the stock.
I expect a BIG nothing burger.
Look at the price/volume graph today. It is clear the the bashers, FUDsters and shorters painted the tape at the close of trading for AVXL at 4:00 PM EDT.
Good luck and GOD bless,
Only plausible one is Missling retiring soon, like really soon please.
ALZ EMA application they are not ready nor have staff for those Millions of pages.
for Rett, FDA already said we need a new trial. Check back in 2028 for results if trial is ever started.
This “growth strategy” term seems pretty general. But it could give the sp a significant boost if the “strategy” is to apply for EMA approval “next week”, FDA approval for Rett “next week” and Missling’s retirement “next week.” He seems to be all about the money so a sp boost would fall in line with him cashing out. Maybe not $5 to $100 but could be a significant rise. But, then again, maybe not.
I don’t think that partnerships are based on approval but I do think that the FDA needs to be assured that all the boxes are checked off. That is probably one of the reasons why most small biotechs have partnerships early on. I guess avxl has decided that you get better value when partnering after results but before approval or at least I hope it is that way. I would hate to think that we will have to wait another 10 months for the stock to move.
Chris, as to disclosure, if partnerships are based on approval, do they need to be revealed before approval decision is received?
I don’t like to rewrite history. Plus, I can’t edit a post on the mobile app.
Um... It is possible to correct an error in a post when you see it right away.
DUH !!!!!!
2-73 failed AD, Rett , inability to do Parkinson's
according MayoMobile update
but TBSD never tell us that
put TBSD in jail
Pumpers are nickel-and-diming it with back-of-the-napkin sales projections and stock prices for a drug that won't even make it to NDA filing. But hey, dreams are free
"made enough money selling most of my stock in the high $20s" You must have caught the June 2021 peak or close to the peak. I caught the one on Feb 3 and Feb4 During the say on Feb 3 2021 we went up considerable amount. But it went CRAZY in the afterhours and Pre-Hours of Feb4 2021. I parted with my shares. Could have easily bought a new Mercedes. Sold all in the 19 to 21 price range. Probably one of these days we will get another shot at another serious spike.
John k9uwa
BIOchecker
If I may, you post very often...if this is the turd you opine, why do you post so often?
You seem intelligent, so there must be a plethora of other equities you would enjoy to post about, extolling their value
Let's see a pic of that vanity plate. If it looks good I may want one myself.
You conveniently failed to mention in your post that I’ve been right about Anavex for 7 years. You know who else has gotten it right for the last 7 years? Short sellers. You know who’s gotten it wrong for 7 years? WGTers.
I actually made enough money selling most of my stock in the high $20s during the brief period of irrational exuberance to buy a new Mercedes with plenty to spare. My vanity plate is A2-73. Ironic, isn’t it? Hahahaha!
Why didn’t you sell yours at $6.80? Dang it!
That you have been fired by your handlers, Ziggy.
Nothing but all negative posts for 7 years. Lol
For 7 years constantly. Go figure. SMH
And on that day your name will become extremelycreamyzig.
“ I think it was you that said a stock can go from $5 to $100 overnight. ”
This imo was much more possible in a “less algorithmic” trading world. Now the MM’s (casino owners) has AI watching trends on “moods” in chat rooms, trading activity, how many times people click on or stay in stocks, and worst of all they employ marauders to influence the outcome they desire one way or another.
Big news will eventually win out but the days of racing to $100 is very controlled on the way up and down imo.
Only green stock of the day. Someone must know something right, George?
- Article leak?
- PDD full data leak?
- Biogen done testing 2-73 leak?
- Schizo leak?
- EU Marketing Application leak?
- FDA Accelerated of the Accelerated Acceleration approval leak?
- Dizziness among the older crowd as a side effect listed as a plus?
What could it be?
I love that guy...the world is ending! But yes...what I said of George is true.
The only way that we can get a massive price in a buyout is to achieve a share price that is roughly half that price, or more, before the buyout. In our case, that can only happen with approvals and revenue.
The question at that time is, do you really want it, or would it be better for the company to grow independently.
Gary
Anavex has a good story. The science seems believable. The management has made missteps. I've made money here as a long. The current scenario of a rising price on lower than average volume is intriguing. Let's see how this plays out with both the shorts and longs making their respective bets.
And yes, I'll continue to try and point out the unfounded pumping dream shite.
That is an outright lie.
Here is the truth:
And there is no way that these same people have been consistently short during the many years they’ve been here obsessed with convincing people of imminent doom. This is a giveaway that they are sponsored by an institution, read hedge fund and/or mm which, in some cases, are effectively the same entities.
power--" partnership with Consortium members or other BP will happen "--thanks for the response--works for me !!WGT !!!
Not quite sure about overnight, but in a very short term.
BMS acquired Karuna for a 53% premium to Karuna’s stock price prior to the acquisition. A similar premium for Anavex would put the acquisition price at around $6.00.
Go back and look at Karuna from the time of its IPO in 2019. From then and going forward it was everything that Anavex is not. You can start with this fact: Goldman Sachs & Co. LLC and Citigroup acted as joint book-running managers for the IPO. Wells Fargo Securities also served as a joint book-running manager. Wedbush PacGrow acted as co-manager.
Keep dreaming, ‘cause that’s all you got.
There are those here on the board that have an agenda. The majority that read the board are shareholders and are interested in keeping up with their investment.
The shareholders have a vested interest. The shorts also have a vested interest 22,000,000 shares are short with a value of close to $100,000,000.
I suggest that the shareholders are a much larger group with much less concentrated ownership whereas the shorts I suggest have much more concentrated ownership (shortership?) and are therefore in a much better position to try to exert influence on the share price. That is, they have more resources to work with and a clearer objective.
Just watch how many posts will immediately tell me that it is all my imagination. Nothing to see here, move along.
I think it was you that said a stock can go from $5 to $100 overnight. Evidently for reasons that it has allegedly happened before. I'll go with that guess and rationale for now. 🤪
Notice how the fudsters protest if someone suggests that Dr. Jin, for example, chose Anavex, because he sees its potential. But somehow the opposite suggestion regarding the COO leaving is of course a harbinger of doom.
I doubt the FDA gives two hoots in a high wind about whether the EMA approves 2-73 first. Until Anavex files an NDA the FDA doesn't have any option about approval.
Since you seem to know so much about Stephan Toutain can you tell us how many options he had and how many shares he owned?
We have seen the pay package he is getting at his new job and it appears to be much better than what he had at Anavex.
I think the canary is being overcome from the fumes of the BS you are laying down.
Followers
|
1067
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
458520
|
Created
|
12/18/07
|
Type
|
Free
|
Moderators RedShoulder Steady_T Bourbon_on_my_cornflakes kund mike_dotcom nidan7500 |
Anavex®Life Sciences Corp. (the “Company”) is a clinical stage biopharmaceutical company engaged in the development of differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental diseases including drug candidates to treat Alzheimer’s disease, other central nervous system (“CNS”) diseases, pain and various types of cancer. The Company’s lead compound ANAVEX®2-73 is being developed to treat Alzheimer’s disease, Parkinson’s disease and potentially other central nervous system diseases, including rare diseases, such as Rett syndrome.
Anavex®Life Sciences’ lead drug candidate, ANAVEX®2-73, recently completed successfully a Phase 2a clinical trial for Alzheimer’s disease. ANAVEX®2-73 is an orally available drug candidate that restores cellular homeostasis by targeting sigma-1 and muscarinic receptors. Preclinical studies demonstrated its potential to halt and/or reverse the course of Alzheimer’s disease. It has also exhibited anticonvulsant, anti-amnesic, neuroprotective and anti-depressant properties in animal models, indicating its potential to treat additional CNS disorders, including epilepsy and others. The Michael J. Fox Foundation for Parkinson’s Research has awarded Anavex® a research grant to develop ANAVEX®2-73 for the treatment of Parkinson’s disease to fully fund a preclinical study, which could justify moving ANAVEX®2-73 into a Parkinson’s disease clinical trial. ANAVEX®3-71, also targeting sigma-1 and M1 muscarinic receptors, is a promising preclinical drug candidate demonstrating disease modifications against the major Alzheimer’s hallmarks in transgenic (3xTg-AD) mice, including cognitive deficits, amyloid and tau pathologies, and also with beneficial effects on neuroinflammation and mitochondrial dysfunctions.
The Company is in preparation for ANAVEX®2-73 for a Phase 2/3, placebo-controlled trial in Alzheimer’s disease as well as a Phase 2, placebo-controlled trial in Rett syndrome, for which the U.S. Food and Drug Administration (FDA) granted Orphan Drug Designation (ODD) for ANAVEX®2-73 and a Phase 2, placebo-controlled trial in Parkinson’s disease.
Headquartered in New York, Anavex® Life Sciences is an American publicly traded corporation on Nasdaq quoted as AVXL
.Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |